In hematological malignancies, PTEN promoter was found hypermethylated in 20% of acute lymphoblastic leukemia and chronic myeloid leukemia cases, and it is also involved in the mechanism determining imatinib resistance [17]. The gene discussed is PTEN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.